Vyvanse Mental Health and Mood Impact: What the Clinical Evidence Actually Shows

What the label says about mood and psychiatric risk

Vyvanse is lisdexamfetamine, an inactive prodrug that the body converts to dextroamphetamine [1]. Its label has a psychiatric adverse-reactions section built around three risks. Stimulants may worsen behavior disturbance and thought disorder in people who already have a psychotic disorder. They may induce a manic or mixed episode in people with bipolar disorder. And at recommended doses they may cause new psychotic or manic symptoms (hallucinations, delusional thinking, mania) in people with no such history: in a pooled analysis of short-term placebo-controlled stimulant trials this occurred in about 0.1% of treated patients versus 0% on placebo [1].

The label says to screen for risk factors for a manic episode before treatment starts, naming a history of depressive symptoms and a family history of suicide, bipolar disorder or depression, and says to consider discontinuing Vyvanse if new psychotic or manic symptoms appear [1]. The only boxed warning on the label is about abuse, misuse and addiction, not mood [1].

Anxiety, jitteriness and irritability: the trial counts

In the 4-week adult ADHD trial (358 people on Vyvanse, 62 on placebo), anxiety was reported by 6% versus 0%, feeling jittery by 4% versus 0%, agitation by 3% versus 0% and restlessness by 3% versus 0% [1]. In children aged 6 to 12 the mood-related entries were irritability at 10% versus 0% and affect lability at 3% versus 0% [1]. Anxiety is one of the reactions the label lists as occurring in 2% or more of patients and at least twice the placebo rate in ADHD trials [1].

The binge eating disorder trials showed the same pattern at lower frequency: anxiety 5% versus 1% and feeling jittery 6% versus 1% [1].

A 2025 meta-analysis of 93 randomized trials of methylphenidate, lisdexamfetamine and other amphetamines found a higher risk of any adverse event than placebo (risk ratio 1.34, 90% CI 1.27 to 1.41), and the result held when lisdexamfetamine was analyzed separately [2].

Insomnia: the sleep effect the label counts in every population

The label quantifies insomnia in each population studied: 27% versus 8% in adults with ADHD, 22% versus 3% in children aged 6 to 12, 13% versus 4% in adolescents 13 to 17, and 20% versus 8% in adults with binge eating disorder [1]. In a laboratory school study of children aged 6 to 12, insomnia was reported by 27% during open-label dose optimization and by 4% during the placebo-controlled crossover phase [3].

The label says Vyvanse is taken in the morning with or without food, and that afternoon doses are avoided because of the potential for insomnia [1].

Can Vyvanse trigger mania or psychosis?

The psychiatric warning covers central nervous system stimulants as a class, and the rate it gives for new psychotic or manic symptoms at recommended doses is about 0.1% versus 0% on placebo in pooled short-term trials [1]. A Swedish registry study of a different stimulant, methylphenidate, followed 2,307 adults with bipolar disorder who started it: the rate of manic episodes was higher in the first three months when methylphenidate was used alone (hazard ratio 6.7, 95% CI 2.0 to 22.4) and lower when a mood stabilizer was taken with it (hazard ratio 0.6, 95% CI 0.4 to 0.9) [4]. That study did not test lisdexamfetamine.

Does Vyvanse help or worsen depression?

Vyvanse is not approved for depression. Its indications are ADHD in patients 6 and older and moderate to severe binge eating disorder in adults [1].

A proof-of-concept placebo-controlled trial tested it as an add-on in depression; it was exploratory, and Vyvanse is not approved for depression. In Trivedi et al. (J Clin Psychiatry 2013), adults with residual depressive symptoms after 8 weeks of open-label escitalopram were randomized to 6 weeks of lisdexamfetamine 20 to 50 mg/day or placebo. Among those who had not remitted (64 on placebo, 65 on lisdexamfetamine), the Montgomery-Asberg Depression Rating Scale score fell more with lisdexamfetamine, with a least-squares mean difference of -2.3 points (90% CI -4.5 to -0.1, P=.0902). That met the trial's prespecified alpha of .10 rather than the usual .05. The number needed to treat for remission was 6.7, and among patients who had already remitted the difference was not statistically significant (1.2 points, 90% CI -1.6 to 4.0) [5].

What happens to mood when Vyvanse is stopped

The label's drug abuse and dependence section says that after prolonged use, withdrawal can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor changes [1].

Vyvanse with antidepressants: what the label says to watch for

Serotonin syndrome, a potentially life-threatening reaction, can occur when amphetamines are combined with drugs that affect serotonin: MAOIs, SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's wort. CYP2D6 inhibitors may raise exposure to dextroamphetamine and add to the risk; the label says to start at lower doses and monitor for signs and symptoms during initiation and after dose increases, and to stop both drugs if serotonin syndrome occurs [1].

MAOIs are contraindicated, during treatment and for 14 days after stopping one, including linezolid and intravenous methylene blue. The label says MAOIs slow amphetamine metabolism and can cause hypertensive crisis, toxic neurological effects and malignant hyperpyrexia [1].

The label also says tricyclic antidepressants may have enhanced activity when combined with amphetamines, with striking and sustained increases in brain d-amphetamine and potentiated cardiovascular effects, and that frequent monitoring is needed [1].

Binge eating disorder: efficacy and mood-related adverse events

Two 12-week placebo-controlled trials in adults with moderate to severe binge eating disorder (n=383 and n=390) tested lisdexamfetamine 50 or 70 mg/day. Binge eating days per week fell more with lisdexamfetamine, with treatment differences of -1.35 days (95% CI -1.70 to -1.01) and -1.66 days (95% CI -2.04 to -1.28), both P<0.001. The most common adverse events were dry mouth, insomnia and headache, and mean pulse rose by 4.41 to 6.31 beats per minute [6].

In a maintenance study, 418 adults entered 12 weeks of open-label lisdexamfetamine and 275 responders were randomized to continue it or switch to placebo for up to 26 weeks. Relapse occurred in 3.7% of those who continued (5 of 136) versus 32.1% of those switched to placebo (42 of 131), hazard ratio 0.09 (95% CI 0.04 to 0.23) [7].

The label's mood-related adverse-event counts in these adults were insomnia 20% versus 8% and anxiety 5% versus 1% on lisdexamfetamine versus placebo [1].